NSF Granted $256K to Predict Severity of COVID Infections

The goal is to prioritize patients coming into the ER to ensure hospital resources are allocated efficiently.

Inherent Biosciences Logo

COVID-19 affects people differently. Sometimes it ravishes the immune system, and attacks the lungs, while other cases are asymptomatic and go unnoticed. A recent Newswire press release announced that a Utah-based biotechnology company called Inherent Biosciences received a grant to study epigenetic biomarkers to predict a patient response to COVID-19 infection. The $255,959 grant comes from the National Science Foundation in an effort to develop on-site clinical tests that screen incoming patients and prioritizes hospital resources based on the predicted infection severity.

More in Quick Hits